Citations

Clear

44 citation(s) found for "Johnson, Emma".

Review of Cutaneous Manifestations in Myhre Syndrome With Histopathological Analyses and Genotype–Phenotype Correlation
Mittal, Setu , Johnson, Emma F. , Schimmenti, Lisa A. , Mohandesi, Nessa Aghazadeh, Aghazadeh, Nessa , Schimmenti, Lisa A , Aghazadeh Mohandesi, Nessa , Mittal, Setu

Mayo Clinic

American Journal of Medical Genetics Part C: Seminars in Medical Genetics | February 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmgc.70005 | PMID 41680107 Get It

ABSTRACT Myhre syndrome is a rare multisystem disorder characterized by distinctive facial features, hearing loss, and progressive fibrosis affecting the skin, joints, lungs, and cardiovascular system. It is caused by heterozygous pathogenic variants in the SMAD4 gene. In this review, we detail the cutaneous manifestations observed in two previously reported patients with genetically confirmed Myhre syndrome. While skin biopsies demonstrated pan‐dermal thickening of collagen bundles, the immunohistochemical staining patterns were distinct from those seen in other inflammatory sclerosing disorders. Additionally, we conducted a comprehensive literature review of the cutaneous features associated with Myhre syndrome, identifying 175 patients with confirmed SMAD4 pathogenic variants. The most reported cutaneous finding was thickened or stiff skin (76%), followed by keratosis pilaris (22%) and impaired wound healing or abnormal scarring (18%). Genotype–phenotype analysis suggested a diagnostic delay in patients with the codon 496 variant, who were more frequently diagnosed in adulthood. This variant may also be associated with a milder cutaneous phenotype, highlighting the clinical heterogeneity of Myhre syndrome. These findings underscore the importance of recognizing cutaneous features as potential early diagnostic clues in patients with suspected Myhre syndrome.
Erosive Mucocutaneous Eruptions in Patients Treated With Immune Checkpoint Inhibitors: A Case Series
Jaroenpuntaruk, Valerie , Johnson, Emma F. , Phillips, Elizabeth J., Alavi, Afsaneh, Alavi, Afsáneh , Cull, Deborah B, Johnson, E F , Alavi, A , Cull, Deborah , Phillips, Elizabeth J.

Mayo Clinic

International Journal of Dermatology | January 14, 2026 | Volume: 65 | Issue: 7 | Pages: 1512-1515

10.1111/ijd.70279 | PMID 41531100 Get It

Enhanced detection of dermal-binding autoantibodies in pemphigoid diseases with a modified indirect immunofluorescence cell-based mosaic assay using IgG4 and optimized testing conditions: a single-centre retrospective study
Agrawal, Shruti , Camilleri, M. J., Comfere, Nneka I. , Johnson, Emma F. , Kalaaji, Amer N., Wieland, Carilyn N. , Lange, Colleen R., Miller, C., Shore, Carly J, Guerrico, Anatilde M Gonzalez, Lange, Colleen, Miller, Cameron, Gonzalez Guerrico, Anatilde M, Lehman, Julia S. , Guerrico, Anatilde M. Gonzalez

Mayo Clinic

British Journal of Dermatology | January 9, 2026 | Volume: 195 | Issue: 1 | Pages: 187-188

10.1093/bjd/ljag007 | PMID 41517990 Get It

Patzelt et al. previously characterized dermal-binding autoantibodies using an indirect immunofluorescence (IIF) mosaic assay with cells transfected with p200-laminin β4, laminin-332 or collagen VII subunits among specimens showing a dermal pattern on IIF using salt-split skin (IIF-SSS) and IgG. This study expanded testing to include specimens with either a dermal or mixed pattern on IIF-SSS and demonstrated improved test sensitivity with modified testing methods.
Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up
Kumar, Shaji, Mateos, María‐Victoria , Ye, J Christine, Magen, Hila , Trudel, Suzanne , Richter, Joshua R. , Chuah, Hun , Yoon, Dok Hyun, Matous, Jeffrey, Dachs, Laura Rosiñol, Onodera, Koichi , Maffucci, Carmela, Heuck, Christoph, Henninger, Todd, O’Rourke, Lisa, Thakkar, Payal, Festa, M, Zhou, Jiangxiu, Takamoto, Mikihiro, Pei, Lixia, Lu, Jiashen, Au, Nicholas T., Krevvata, Maria, Cohen, Yaël C. , Usmani, Saad Z. , Kumar, Shaji , Atrash, Shebli , Quach, Hang , Chu, Michael, Rodríguez‐Otero, Paula , Gatt, Moshe E. , Medvedova, Eva , Raza, Shahzad , Yoon, Dok Hyun , Ishida, Tadao , Scott, Emma , Zhang, Jing , Festa, Mariacristina, Huang, Lin , Lu, Jiashen

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 698-698

10.1182/blood-2025-698 Get It

Abstract Introduction: Patients (pts) with soft tissue plasmacytomas noncontiguous with bone (true extramedullary disease [EMD]) have poor outcomes with standard therapies shown by low overall response rates (ORRs), which are not durable. Talquetamab (Tal; anti-GPRC5D×CD3) and teclistamab (Tec; anti-BCMA×CD3) are first-in-class bispecific antibodies (BsAbs) approved as monotherapies for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Primary analysis from the RedirecTT-1 (NCT04586426) dedicated phase 2 EMD cohort (March 2025 data cut; median follow-up [mFU] 12.6 mo) showed Tal + Tec elicited an ORR of 78.9% (assessed by independent review committee) and a 12-mo progression-free survival (PFS) of 61.0%. Here, we report updated efficacy, using investigator assessment, and safety results from the phase 2 RedirecTT-1 EMD cohort with Tal + Tec. Importantly, we report EMD location and a novel analysis of tumor burden as a prognostic indicator of ORR. Methods: Pts had TCE RRMM and true EMD defined as ≥1 nonradiated soft tissue plasmacytoma noncontiguous with bone ≥2 cm in 1 dimension (with or without paramedullary plasmacytomas). Nonsecretory/oligosecretory disease was permitted. Prior CAR-T and non-BCMA/-GPRC5D BsAb therapies were permitted. Pts received Tal 0.8 mg/kg + Tec 3.0 mg/kg Q2W, preceded by step-up doses, with a permitted switch to monthly dosing at investigator's discretion after cycle 6 or after cycle 4 with confirmed ≥VGPR. Response was assessed per IMWG; EMD response was assessed by PET-CT or MRI whole-body scans. Tumor burden was assessed by total EMD tumor volume. Results: As of July 2025, 90 pts received Tal + Tec, with a median follow-up of 16.3 mo (range 0.5–23.7). Baseline characteristics were as previously reported; 39% had nonsecretory/oligosecretory disease, 20% had prior anti-BCMA CAR-T therapy, and 9% had prior BsAb therapy (all anti-FcRH5). The median number of plasmacytomas was 2 (range 1–7); 17 (18.9%), 29 (32.2%), and 74 (82.2%) pts, respectively, had ≥1 nodal, organ, or soft tissue EMD, while 11 (12.2%) also had ≥1 additional paramedullary plasmacytoma. Of 268 EMDs across all pts, 95 (35.4%) were nodal EMD, 77 (28.7%) were organ EMD (most commonly liver), and 64 (23.9%) were soft tissue EMD; 32 (11.9%) were paramedullary. Baseline EMD tumor volume was <25 cm2in 43 (47.8%) pts, 25–50 cm2 in 21 (23.3%) pts, and >50 cm2 in 26 (28.9%) pts. Per investigator assessment, ORR (95% CI) was 77.8% (67.8–85.9); 50.0% had a ≥CR. Median duration of response (DOR) was not estimable (NE; 12-mo DOR rate, 60.1%), 12-mo PFS was 55.6%, and median overall survival (OS) was NE (12-mo OS rate 73.8%). ORR was 90.7% (77.9–97.4; ≥CR 60.5%) in pts with EMD tumor volume <25 cm2, 66.7% (43.0–85.4; ≥CR 52.4%) for 25–50 cm2, and 65.4% (44.3–82.8; ≥CR 30.8%) for >50 cm2. Common adverse events (AEs) included CRS (77.8%; no grade [gr] 3/4) and neutropenia (72.2%; gr 3/4 62.2%). Taste changes (78.9%), non-rash skin AEs (68.9%), and nail AEs (55.6%) were all gr 1/2, and rash AEs (30.0%) were mostly gr 1/2. ICANS occurred in 11 (12.2%) pts (gr 3, 1.1%; gr 4, 1.1%). Infections occurred in 72 (80.0%) pts (gr 3/4 40.0%), most commonly upper respiratory tract infection (26.7%; gr 3/4 5.6%); IVIG was highly recommended to prevent and manage hypogammaglobulinemia and infection. Ten (11.1%) pts discontinued Tal + Tec due to treatment-emergent AEs (4 pts due to infections and 6 due to gr 5 AEs). Two pts discontinued Tal only due to AEs. In total, 11 (12.2%) pts had gr 5 AEs (6 due to infections), 6 of which were deemed to be drug related by investigators. Data will be updated with an additional 4 mo of follow-up for the presentation. Conclusions: With longer follow-up in pts with TCE RRMM with true EMD regardless of baseline tumor characteristics, Tal + Tec efficacy exceeded all approved therapies, including T-cell redirecting and cellular therapies, noting limitations of cross-study comparisons. Lower total EMD tumor volume was associated with a higher ORR but low pt numbers in each group and lack of statistical testing limits robust interpretation. The safety profile of Tal + Tec was generally consistent with each monotherapy; AEs were not exacerbated with the combination. These data continue to highlight the clinical benefit of the novel combination of Tal + Tec in pts with true EMD, a population with high disease burden and significant unmet need.
Genome-wide association studies identify 77 loci for suicidality and provide novel biological insights
Colbert, Sarah M. C. , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud, Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I, Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris, Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette, Euler, Sebastian, Falkai, Peter, Fanelli, Giuseppe, Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip, Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs, Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Holla, Bharath, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary S, Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A, Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pisanu, Claudia, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas G, Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus, Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E, Docherty, Anna R. , Mullins, Niamh , Roberts, Gloria , Pisanu, Claudia , Holla, Bharath , Fanelli, Giuseppe , Ruderfer, Douglas , Docherty, Anna R , Mullins, Niamh , Pisanu, Claudia , Koromina, Maria, Hatoum, Alexander S, Stephenson, Mallory, Edwards, Alexis C, Johnson, Emma C, Qin, Xuejun, Shabalin, Andrey A, Ito, Lucas T, O’Connell, Kevin S, Harder, Arvid, Hjerling-Leffler, Jens, Kim, Min Ji, Otsuka, Ikuo, Vilar-Ribó, Laura, Agrawal, Arpana, Alda, Martin, Alfredsson, Lars, Aliev, Fazil, Andlauer, Till FM, Arango, Celso, Arntz, Arnoud R. , Awasthi, Swapnil, Ayinde, Olatunde O, Bacanu, Silviu-Alin, Barr, Peter B, Bau, Claiton HD, Baune, Bernhard T, Beckham, Jean C, Bejan, Cosmin A, Belangero, Sintia, Berger, Klaus, Biernacka, Joanna M, Bogdan, Ryan, Boomsma, Dorret I , Børglum, Anders D, Bourassa, Kyle J, Braff, David L, Braun, Alice, Bressan, Rodrigo A, Brueckl, Tanja M, Budde, Monika, Cabrera-Mendoza, Brenda, Carpiniello, Bernardo, Ceja, Zuriel, Cervilla, Jorge A, Chang, Chiao-Erh, Chaumette, Boris , Cheon, Myeong Jae, Cichon, Sven, Coleman, Jonathan RI, Coon, Hilary, Copeland, William E, Czamara, Darina, Dalkner, Nina, Dannlowski, Udo, David, Friederike S, Demontis, Ditte, Florio, Arianna Di, Diaconu, Carmen C, Dick, Danielle M, Dikeos, Dimitris, Djurovic, Srdjan, Edenberg, Howard J, Erlangsen, Annette , Euler, Sebastian, Falkai, Peter , Fellendorf, Frederike T, Ferentinos, Panagiotis, Fernandez-Aranda, Fernando, Forstner, Andreas J, Frei, Oleksandr, Fries, Gabriel R, Fullerton, Janice M, Gaine, Marie E, Galfalvy, Hanga C, Galimberti, Marco, Garcia-Aymerich, Judith, Garrett, Melanie E, Gawlik, Micha, Gelernter, Joel, Gordon-Smith, Katherine, Gorelik, Aaron J, Gorwood, Philip , Grabe, Hans J, Green, Melissa J, Grigoroiu-Serbanescu, Maria, Gupta, Priya, Gutiérrez, Blanca, Guzman-Parra, Jose, Han, Seonggyun, Haram, Marit, Hauser, Elizabeth R, Heilbronner, Urs , Herpertz, Sabine C, Herrera-Imbroda, Jesús, Hesselbrock, Victor M, Hishimoto, Akitoyo, Izotova, Anastasia, Jang, Yoonjeong, Jimenez-Murcia, Susana, Jones, Lisa A, Jonsson, Lina, Kang, JooEun, Kang, Joon Ho, Keel, Pamela K, Kim, Jaeyoung, Kim, Dongjun, Kircher, Tilo, Kirov, George, Kraft, Julia, Kramer, John, Kranzler, Henry R, Kuo, Po-Hsiu, Kurvits, Siim, Lai, Dongbing, Lake, Marilyn T, Landén, Mikael, Lannoy, Séverine, Law, Matthew H, Lee, Byung-Chul, Lee, Young Kee, Lehto, Kelli, Levey, Daniel F, Lewis, Cathryn M, Li, Qingqin S, Liao, Calwing, Lind, Penelope A, Lochner, Christine, Lori, Adriana, Maes, Hermine HM, Mahadevan, Jayant, Manchia, Mirko, Mars, Becky, Martin, Nicholas G, Martorell, Lourdes, McIntosh, Andrew M, McMain, Shelley F, McQuillin, Andrew, Medland, Sarah E, Mitchell, Philip B, Molina, Esther, Monson, Eric T, Mufford, Mary Sophia , Muntané, Gerard, Musil, Richard, Myung, Woojae, Neagu, Ana Iulia, Nielsen, Trine T, Nöthen, Markus M, Nunez, Yaira Z, Nurnberger, John I, Okazaki, Satoshi, Olsen, Catherine M, Ophoff, Roel A. , Owen, Michael J, Pan, Pedro M, Papiol, Sergi, Pascual, Juan C, Patrinos, George P, Pawlak, Joanna M, Penninx, Brenda WJH, Pérez-Gutiérrez, Ana M, Perroud, Nader, Peterson, Roseann E, Pistis, Giorgio, Porjesz, Bernice, Posthuma, Danielle, Powers, Abigail, Preisig, Martin, Purushottam, Meera, Reif, Andreas, Reininghaus, Eva Z, Rentería, Miguel E, Ripke, Stephan, Ripperger, Michael A, Rivera, Margarita, Roberts, Emily K, Roberts, Gloria, Rødevand, Linn, Roepke, Stefan, Rovaris, Diego L, Salum, Giovanni A, Sanders, Alan R, Santoro, Marcos L, Sawyers, Chelsea, Scherer, Stephen W, Schilling, Claudia, Schmahl, Christian, Schofield, Peter R, Schulze, Thomas , Scott, Laura J, Serretti, Alessandro, Shadrin, Alexey, Shirai, Toshiyuki, Smeland, Olav B, Smoller, Jordan W, Sokolowski, Marcus , Sonuga-Barke, Edmund J, Squassina, Alessio, Starnawska, Anna, Steen, Nils Eiel, Stein, Dan J, Stein, Frederike, Stein, Murray B, Streit, Fabian, Sud, Reeteka, Sullivan, Patrick F, Terao, Chikashi, Toma, Claudio, Tondo, Leonardo, Turecki, Gustavo, Uher, Rudolf, Ursano, Robert J, Auwera, Sandra Van der, Vawter, Marquis P, Paska, Alja Videtic, Vilella, Elisabet, Vincent, John B, Viswanath, Biju, Vladimirov, Vladimir, Wasserman, Danuta E, Weickert, Thomas W, Whiteman, David C, Willour, Virginia L, Wiström, Erik D, Witt, Stephanie H, Won, Hong-Hee, Wootton, Robyn E, Zai, Clement C, Zhang, Jian, Zillich, Lea, MGL, CVEDA and, Andreassen, Ole A, Palmer, Abraham A, Sanchez-Roige, Sandra, Mann, J John, Kimbrel, Nathan A, Ashley-Koch, Allison E

Mayo Clinic

No container title available | October 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.10.22.25338076 | PMID 41282879 Get It

ABSTRACT Suicidality contributes substantially to global morbidity and mortality, yet despite its heritability, its biological etiology remains largely elusive. We conducted multi-ancestry genome-wide association study meta-analyses of suicidal ideation (259,747 cases), suicide attempt (64,993 cases), suicide death (9,197 cases), and suicidal behavior (suicide attempt/ death, 75,300 cases), across 54 cohorts (e.g., the Psychiatric Genomics Consortium, Million Veteran Program, UK Biobank). We identified 77 significant loci across meta-analyses, including 59 previously unreported for suicidality. SNP-based heritability ranged from 2.0-6.7% and there were strong, yet incomplete, genetic correlations between suicidality phenotypes (0.70-0.88). Fine-mapping prioritized putative causal SNPs and 20 credible genes. Enrichment analyses implicated synaptic pathways and neuronal populations predominantly in subcortical brain regions (e.g., amygdala excitatory, medium spiny, hippocampal CA1-3). Together, these findings establish suicidality as a polygenic set of traits with both shared and distinct genetic influences, providing a foundation for future studies of suicide biology and etiology.
Cutaneous Limited Langerhans Cell Histiocytosis Complicated by Late-onset Panhypopituitarism
Ahmed, Nehaal , Davidge‐Pitts, Caroline , Johnson, Emma F. , Johnson, Emma , Young, Jason , Go, Ronald S.

Mayo Clinic

JCEM Case Reports | June 18, 2025 | Volume: 3 | Issue: 9 | Pages: No page available

10.1210/jcemcr/luaf138 | PMID 40727480 Get It

Abstract Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder infrequently complicated by delayed-onset pituitary disease. A 41-year-old female presented with papular, acneiform skin lesions. Shave biopsy demonstrated a superficial dermal epithelioid cell proliferation with S100, CD1a, and langerin positivity on immunohistochemistry and a BRAF p.N486_P490del inframe deletion-gain of function pathogenic variant on next-generation sequencing. The skin lesions spontaneously resolved. One year later, she developed progressive fatigue, fevers, anorexia, menstrual irregularities, polyuria, and polydipsia. Laboratory workup was consistent with panhypopituitarism. Pituitary magnetic resonance imaging noted mass-like thickening and enhancement of the infundibulum extending toward the hypothalamus. After treatment with cobimetinib, magnetic resonance imaging findings resolved but endocrinopathies persisted, requiring indefinite hormone therapy. This case demonstrates the full spectrum of endocrinopathies of LCH-induced pituitary disease and is an unusual circumstance of LCH with delayed-onset panhypopituitarism.
Histopathologic Features in Vancomycin‐Associated Drug‐Induced Hypersensitivity Syndrome
Haberecht, Hannah, Ziebart, Rachel, Iverson, Olivia , Todd, Austin, Davis, Mark D. P. , Wetter, David A. , Sartori‐Valinotti, Julio C. , McEvoy, Marian T., Aghazadeh, Nessa , Johnson, Emma F. , Haberecht, Hannah B , Ziebart, Rachel L, Iverson, Olivia C, Davis, Mark D., Cantwell, Hafsa M. , Aghazadeh Mohandesi, Nessa , Ziebart, Rachel L , Davis, Mark D.P. , Alavi, Afsáneh

Mayo Clinic

Journal of Cutaneous Pathology | March 25, 2025 | Volume: 52 | Issue: 6 | Pages: 442-451

10.1111/cup.14804 | PMID 40129304 Get It

ABSTRACTBackgroundDrug‐induced hypersensitivity syndrome (DiHS), or drug reaction with eosinophilia and systemic symptoms (DRESS), is a delayed and severe immune response to certain medications. We investigated vancomycin‐induced DiHS/DRESS, notable for frequent and severe organ involvement, to describe its specific histopathology and the correlations between histopathologic and clinical findings.MethodsA retrospective review was conducted to identify patients between 2006 and 2022 who received vancomycin, had archived skin biopsy specimens, and were scored as having probable or definite DiHS/DRESS. Clinical features were retrospectively collected, and biopsy specimens were reviewed by a board‐certified dermatopathologist. A subset of histopathologic and clinical features was analyzed for statistical correlation.ResultsTwenty‐three patients met the inclusion criteria. Most biopsy specimens (87%) showed an eczematous reaction pattern; 17 (74%) showed a secondary reaction pattern. Spongiosis (87%) and neutrophilic infiltration (91%) were common epidermal characteristics. The dermal inflammatory infiltrate was frequently superficial (87%) and consistently included plasma cells (96%). Eosinophils were present in the dermis in 70% of cases. Parakeratosis negatively correlated with liver involvement and positively correlated with desquamative rash. Epidermal lymphocytes were negatively correlated with the RegiSCAR score.ConclusionsVancomycin‐associated DiHS/DRESS histopathology was characterized by a frequent eczematous reaction pattern, multiple coexisting reaction patterns, and epidermal neutrophilic infiltration.
P16-Negative, High-Risk Human Papilloma Virus-Associated Penile Squamous Cell Carcinomas
Cheville, John C. , Enninga, Elizabeth Ann L. , Johnson, Emma F. , Whaley, Rumeal D. , Hernandez, Loren P. Herrera , Jiménez, Rafael E. , Gupta, Sounak , Herrera Hernandez, Loren P, Enninga, Elizabeth Ann L , Tekin, Burak , Norgan, Andrew P. , Erickson, Lori A. , Guo, Ruifeng

Mayo Clinic

The American Journal of Dermatopathology | March 19, 2025 | Volume: 47 | Issue: 7 | Pages: 564-565

10.1097/dad.0000000000002960 | PMID 40105298 Get It

Smooth, Firm, Skin-Colored Papules on the Nasal Dorsum
Hutson, Seneca D, Lohman, Mary E. , Johnson, Emma F.

Mayo Clinic

JAMA Dermatology | January 8, 2025 | Volume: 161 | Issue: 2 | Pages: 214

10.1001/jamadermatol.2024.5542 | PMID 39775814 Get It

A healthy 19-year-old man with Fitzpatrick skin type V presented with a 2-year history of smooth, firm, skin-colored papules on the nasal dorsum and bilateral alae. What is your diagnosis?